Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Imunon
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
NRG Oncology
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
Akeso
Shanghai Shengdi Pharmaceutical Co., Ltd
Merck Sharp & Dohme LLC
AGO Study Group
CanariaBio Inc.
Merck Sharp & Dohme LLC
National Institute of Cancerología
Assiut University
Mario Negri Institute for Pharmacological Research
University College, London
Huazhong University of Science and Technology
AbbVie
Hoffmann-La Roche
Grupo Español de Investigación en Cáncer de Ovario
AstraZeneca
Women's Cancer Care Associates, LLC
Huazhong University of Science and Technology
Advenchen Laboratories, LLC
Leiden University Medical Center
University Hospital, Toulouse
Seoul National University Hospital
pharmaand GmbH
Shandong University
National Cancer Institute, Naples
National Cancer Institute, Naples
National Cancer Institute, Naples
Hoffmann-La Roche
Morphotek
Qilu Pharmaceutical Co., Ltd.
GOG Foundation
AGO Study Group
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University